Welcome to my Home Page!

    To Japanese pages

    To German pages


Translation Samples

Want to observe acupuncture in Japan? Take a look here 


"It is my job to ensure, that patients do NOT NEED to see me ..."


I can also be found on some blogs (not all are shown here), but not everything is in English.



"200 mg rebetol mastercard, hiv infection and aids difference."

By: Jonathan Handy

bulletConsultant in Intensive Care Medicine,Royal Marsden Hospital,Honorary Senior Lecturer,Imperial College London


Nature has provided ample evidence for oncogenic mutations in members of signaling pathways hiv infection map usa purchase rebetol 200 mg amex. Stimulation of the ras/raf pathway leads to viral anti-gay protester dies purchase rebetol 200 mg augmented expression of the nuclear proteins jun hiv infection rates heterosexuals cheap rebetol 200mg online, fos data on hiv infection rates order rebetol 200mg without prescription, and myc (retroviral homologues = v- jun, v- fos, v- myc; myc is mutated and rearranged in lymphoid malignancies and amplified in breast cancers), some of which are proteins that induce the expression of other genes (called transcription factors). Thus, every relay node in this signal transduction pathway is a potential site for oncogenic conversion. The complexity of the transformation process is further augmented by the existence of multiple parallel signaling pathways that are promiscuous in their selection of biochemical partners. However, another avenue to cancer is the inappropriate expression of structurally normal proteins. To this end, well-known tumor suppressor genes such as the retinoblastoma gene (Rb-1) and p53 can act as "brakes" to cellular proliferation, and each appears to function through distinct pathways. Rb-1 negatively regulates an important transcription factor, E2F, and the deletion of the Rb gene (as seen in congenital retinoblastoma) or sequestration of its protein product (as seen in the presence of the adenovirus E1A protein, or the human papilloma viral protein, E7) releases the suppression of E2F. As is the case with transforming oncogenes, the presence of a single abnormal tumor suppressor allele is insufficient for cancer to form; lesions at other genetic loci are necessary. For example, both Rb and p53 may need to be inactivated for some primary cells to be rendered immortal, one of the first steps in transformation. The story of p16 reiterates the importance of viewing cancer genetics in the context of signaling relays. The cell exerts exquisite control of this process using redundant systems to induce or to block apoptosis, and some of these control switches are involved in cancer induction and in the response to cancer treatment. The clearest example of an oncogene modulating the apoptotic process is bcl-2, found to be the important oncogene in patients with the t(14q;18q) translocation frequently detected in follicular lymphomas. Therefore, augmented Akt function induced by certain ligand receptor interactions is predicted to have a significant antiapoptotic effect. For example, myc is capable of transforming rat fibroblasts; however, in situations of cellular stress, such as serum starvation or when coupled with exposure to certain chemotherapeutic agents, myc triggers cell death in the same cells. However, when myc and ras are co-introduced into primary murine fibroblasts, unequivocal transformation occurs. In addition, these individuals also harbor a heightened risk for endometrial cancer. The clinical consequence of this molecular defect in humans is the emergence of colon cancers that differ from the sporadic variety and are characterized by fewer ras and p53 mutations, as well as less allelic losses. Lastly, rearrangements of the bcl-2 locus and translocations involving the myc proto-oncogene are found solely in lymphomas. The near exclusivity of the involvement of some of these genes with the induction of specific cancers suggests a potential "gatekeeper" function for these genes. Although the exact mechanism is unclear, such putative gatekeeper genes are responsible for the maintenance of the non-cancerous phenotype in restricted tissue types. Less exclusive oncogene-cancer associations occur more frequently and are also helpful in mapping pathways of cancer progression. Similar findings have been observed in other cancers: p53 mutations are found only in cervical carcinomas not induced by oncogenic papillomaviruses. N- myc amplification remains one of the most potent predictors of poorer survival in childhood neuroblastomas. Thus, oncogene 1038 mutations can be used not only in cancer diagnostics but also as useful markers of prognosis. However, the dissection of the biochemical pathways used by these oncogenes is uncovering interactions that may begin to unify empirical observations of human tumor biology. This is evident in the observation that many oncogenes function as genetic switches in the development of diverse systems such as Drosophila melanogaster (fruit fly). Abnormalities in one such molecular "switch" are found in the homeotic mutation called antennapedia, which induces a condition in which legs develop where antennae are normally found. Thus, at every node of signaling control, perturbations induce aberrations of differentiation and growth. The requirement, however, is that the activated pathway uses ras as an intermediary. Thus, the presence of poor prognostic factors may not necessarily mean irreversibly unfavorable outcomes; instead, the profile of oncogene abnormalities in a particular tumor may be used to choose optimal therapy. Recent advances have placed oncogenes more prominently in public health and, in the process, have moved the field into the realm of cancer prevention. The availability of these genetic tests raises some interesting and, simultaneously, troubling questions: Who should be tested, and how young?

buy rebetol 200 mg on line

Methods for recruiting subjects or identifying the study cohort were not generally reported hiv infection rate san diego proven rebetol 200mg. Sample size varied greatly (ranging from 21 to hiv infection condom purchase 200 mg rebetol amex 1 hiv infection asymptomatic buy 200 mg rebetol otc,014 participants) hiv infection via kissing 200mg rebetol with amex, and seven studies had a sample size greater than 200 participants. Three studies examined the Gyrus Plasmakinetic (bipolar) system328, 334, 335 and another a coagulating intermittent cutting device. Intracapsular perforation was reported in 5% of 522 subjects in the only study reporting this outcome. Intraoperative complications were rarely reported; capsule perforation occurred in 5. Only one of the randomized and the two nonrandomized studies showed a reduction in blood loss or transfusion requirements. Other studies found no significant differences between the treatment group and placebo for blood loss during surgery, excessive or severe bleeding, or clot retention. Yanoshak S, Roehrborn C, Girman C et al: Use of a prostate model to assist in training for digital rectal examination. Roehrborn C, Sech S, Montoya J et al: Interexaminer reliability and validity of a threedimensional model to assess prostate volume by digital rectal examination. Wasson J, Reda D, Bruskewitz R et al: A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. Crawford E, Wilson S, McConnell J et al: Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. Djavan B, Fong Y, Harik M et al: Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Temml C, Brossner C, Schatzl G et al: the natural history of lower urinary tract symptoms over five years. Caine M, Raz S, Zeigler M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Furuya S, Kumamoto Y, Yokoyama E et al: Alpha-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Malloy B, Price D, Price R et al: Alpha1-adrenergic receptor subtypes in human detrusor. Michel M, Bressel H, Goepel M et al: A 6-month large-scale study into the safety of tamsulosin. Chappel C: Selective alpha 1 adrenoceptor agonstis in benign prostatic hyperplasia: rationale and clinical experience. Roehrborn C: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. McNeill S, Hargreave T, Roehrborn C: Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Roehrborn C: Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. Roehrborn C, Van Kerrebroeck P, Nordling J: Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Hartung R, Matzkin H, Alcaraz A et al: Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. Elhilali M: Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Vallancien G, Emberton M, Alcaraz A et al: Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. Lukacs B, Grange J, Comet D et al: History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years. MacDiarmid S, Emery R, Ferguson S et al: A randomized double-blind study assessing 4 versus 8 mg. Andersen M, Dahlstrand C, Hoye K: Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia.

buy rebetol 200 mg online

Tumor cells may release procoagulant materials such as tissue factor-like substances that activate Factor X antiviral ppt buy rebetol 200mg lowest price, the sialic acid portion of secreted mucin hiv infection stories australia purchase 200 mg rebetol with visa, or "thromboplastin-like" substances antiviral agents 200 mg rebetol otc. Although controversy exists concerning the relationship of an occult malignancy and thrombosis antivirus software for mac order rebetol 200 mg overnight delivery, about 10% of patients with a new thrombotic event will subsequently be found to have cancer. Anticoagulant therapy should be initiated in a cancer patient cautiously and only after careful consideration because such patients may have an increased tendency for hemorrhage from 1059 a tumor invading blood vessels or the presence of central nervous system metastasis. Acute symptomatic relief can sometimes be achieved with heparin, occasionally in combination with fresh-frozen plasma to provide clotting factors and cryoprecipitate (to maintain a plasma fibrinogen level of 150 to 200 mg/dL). Leukemoid reactions are defined as a peripheral white blood cell count of greater than 20,000 cells/mm3 without evidence of infection or leukemia. The white blood cell count is generally shifted to the left, with mature neutrophils representing the majority of cells. Clinically, the diagnosis of paraneoplastic leukemoid reaction is made by exclusion of a primary hematologic malignancy such as chronic myelogenous leukemia (see Chapter 176), which is associated with splenomegaly, basophilia, and a left shift of the white blood cells with an increase in all early myeloid progenitors. Pheochromocytomas, uterine fibroids, sarcomas, and aldosterone-secreting tumors are also associated with cancer-associated erythrocytosis. This paraneoplastic syndrome is associated with increased levels of endogenous erythropoietin in 50% or fewer of patients; in some cases, cancer-associated erythrocytosis may be secondary to the overproduction of androgens, prostaglandins, and other, yet unidentified substances. Treatment of the underlying tumor will result in beneficial effects on the cancer-associated erythrocytosis. This condition must be differentiated from a primary hematologic disorder such as a myeloproliferative disorder (chronic myelogenous leukemia or primary thrombocythemia) or a secondary cause (chronic inflammation, severe iron deficiency, acute bleeding, or post-splenectomy status). Despite the elevated platelet count, secondary thrombocytosis is not generally associated with clinical evidence of thrombotic or bleeding disorders. Paraneoplastic nephrotic syndrome usually improves dramatically when the underlying malignancy is successfully treated. Deposition of tumor-associated antigen-antibody complexes can cause membranous glomerulonephritis. Patients often have fever and weight loss, in addition to hepatomegaly, elevated aminotransferase levels, and poor liver synthesizing ability (indicated by an elevated prothrombin time). A liver biopsy may reveal Kupffer cell hyperplasia with fairly non-specific inflammatory changes. In the presence of non-metastatic hypernephroma, treatment directed at the primary lesion generally results in resolution of the syndrome. Pulmonary osteoarthropathy consists of symmetrical clubbing of the nails, active synovitis, and periosteal inflammation of the long bones (often manifested as "arthritis" of the elbows, wrists, knees, or ankles). Other possible etiologies include an immune-mediated response or release of growth factor(s) by the tumor. Pulmonary osteoarthropathy can be differentiated from metastatic bone disease or rheumatoid arthritis by the symmetrical bilateral findings and the absence of rheumatoid factor. Arthritic symptoms may be treated with aspirin and/or non-steroidal anti-inflammatory drugs. Surgery of the primary malignancy may improve the articular complaints, sometimes within hours. Review of recent advances in the pathophysiology of paraneoplastic nervous system disorders. The development of new cytotoxic and endocrine agents and the introduction of biologic therapy based on recombinant synthesis of interferons and cytokines have expanded medical management, as has the treatment of the complications of cancer. The physician also must be familiar with palliative aspects of cancer care, including management of pain (see Chapter 27) and treatment of life-threatening complications (see Chapter 199). This approach is predicated on the availability of specific systemic agents with antitumor activity in advanced cancers of the same histopathology. To a significant extent, cancer is a disease of the elderly, and treatment for many types of cancer in patients older than the age of 65 remains difficult because of the reduced host tolerance to the toxicities of many cancer chemotherapeutic agents. Inasmuch as prognosis for individual patients is currently based on statistical estimates, the physician must evaluate each patient individually in relation to relevant prognostic factors in attempting to develop a treatment plan. Accurate histologic diagnosis and staging critically influence treatment selection. For example, the approach to treatment of T-cell or B-cell lymphomas differs as a function of cell lineage, which often cannot be identified with standard histologic approaches. Assessment of the body burden and spread of cancer by clinical means (staging) is important in developing the treatment plan.

order rebetol 200mg otc

Two Oil Emulsions Material Water Mineral oil F-350 Silicone fluid J208-612 Procedure 1 hiv infection rates australia purchase rebetol 200mg fast delivery. When a separation is run using ether and water hiv infection risk rate proven rebetol 200mg, a separation based upon partition coefficient results hiv infection rate saskatchewan purchase 200mg rebetol. Partition coefficient is a measure of the amount of a compound that ends up in each of two insoluble phases after separation hiv infection in toddlers buy rebetol 200mg without a prescription. While it is quite true, likes dissolve likes, the reality is that no compound stays entirely in one phase or another. The term partition coefficient or (distribution coefficient) is a numerical value that relates to the amount of a compound that partitions in one phase or the other. It is defined as the ratio of concentration of compound in aqueous phase to the concentration in an immiscible solvent, as the neutral molecule. The partition coefficient relates to the ability of a given molecule to be solubilized in a specific solvent when two insoluble solvents are chosen. If one now considers a molecule that has a silicone portion, a water-soluble portion and an oil-soluble portion, it will become clear that the so-called "3D partition coefficient" will become interesting. The current practice of the 3D partition coefficient relates to a separation in three phases: mineral oil, water and F-350 silicone fluid. The results are three numbers: the percentage found in the aqueous phase is the first number, the percentage found in the oil phase is the second number and the final number is the percentage found in the silicone phase. The 3D partition coefficient concept not only applies to compounds that have silicone in the molecule, but also organic compounds that have solubility in silicone. Most interestingly, are Guerbet esters, which because of their branching patterns have full solubility in cyclomethicone and partition into silicone fluid. This concept offers to the formulator a numerical method of selecting components for specific phases in their products. Extraction Technology A number of techniques are known to those skilled in the art for extracting watersoluble actives. In organic chemistry, extraction is a well-known technique for separating chemical constituents. It is a process by which a solute is extracted from a first solvent into a second solvent, where the two solvents are immiscible. One common extraction methodology used in organic chemistry involves combining in a separatory funnel water and diethyl ether. As is well-known to those skilled in this art, ether and water do not mix; without agitation, they rapidly separate into two phases or layers. For example, hot water extraction removes water-soluble materials, leaving behind oil-soluble materials as well as materials that are insoluble either in water or oil. Tinctures, produced by using hydro-alcoholic solutions, are another extraction vehicle well-known to skilled artisans. Propylene glycol is yet another commonly used vehicle to extract water-and alcohol-soluble materials. Food and Drug Administration, certain consumer groups have raised health concerns regarding short and long-term health consequences about use of propylene glycolperse, attempting to implicate its use with conditions ranging from skin irritation and sensitization to potential reproductive and development toxicity. A process has recently been developed for the extraction of actives from botanical materials using a series of silicone compounds having different partition coefficients. The different partition coefficients are obtained by varying the ratio of silicone-soluble, water-soluble, oil-soluble and fluoro-soluble groups on the silicone polymer. The phrase "partition coefficient" is understood to mean the equilibrium distribution of the solute between the two immiscible solvent phases. When an organic compound is placed into a solvent mixture of ether and water, it separates, or partitions, into the water and ether phases. At equilibrium, the ratio of the concentrations of the organic solute in each of the solvent layers is its partition coefficient. As is well-known to those of skill in the art, extracting a compound with an ether/water partition coefficient of 80 will result in 80% extraction of the material during each separation procedure. It is also well-known to those of skill in the art that extraction procedures of the type described above are, by their very nature, inefficient. In the example of a 1,000 mg sample of botanical material having an ether/water partition coefficient of 80, after a first pass in a separatory funnel, 800 mg of the botanical will be extracted into the ether phase. The second pass, for example, is expected to remove 140 additional mg, or 80% of the ether-soluble botanical components.

Buy rebetol 200 mg on line. HIV TRI-DOT.